Evidence quality 4.0/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 4/5
≈ As likely as
Perceived
During 2019–2020, US media coverage of the EVALI outbreak — dozens of teenagers hospitalized with mysterious lung injury after vaping — produced intense parental fear about vaping-related respiratory harm. The images of previously healthy teens on ventilators were vivid and specific. The fear persists in the post-outbreak period even though the outbreak was traced to a specific adulterant (vitamin E acetate in illicit THC cartridges) that was largely removed from the supply after the CDC investigation. Current fear about vaping may conflate outbreak-era EVALI risk with ongoing nicotine-vape or nicotine-free vaping.
Source: editorial intuition, not polled
Actual
~2,807 hospitalizations in US over the 2019–2020 outbreak window; outbreak rate ~1 in 1,070 US teen/young-adult vapers
US adolescents and young adults who vaped during the 2019–2020 EVALI outbreak (CDC EVALI case count over an internal ~3M working-estimate denominator; the cited 2019 NYTS anchor puts current youth e-cigarette users at ~5.3M)
Show derivation
CDC EVALI surveillance: 2,807 hospitalized cases and 68 deaths by February 2020 (when CDC stopped active surveillance after the primary causative agent — vitamin E acetate in THC cartridges — was identified and largely removed from the supply). ~82% of cases involved THC-containing products; 57% involved both THC and nicotine. Denominator: an internal ~3,000,000 working estimate for teens + young adults who vaped during the peak window (NOT a directly cited published survey total). For scale, the cited 2019 NYTS anchor (Cullen et al., JAMA) puts current youth e-cigarette users at ~5.3 million (4.1M high school + 1.2M middle school), and the EVALI case series had a median age of 21 — so the true exposed population (adding college-age young adults) is likely ≥5 million. Using the internal 3 million denominator: 2,807 / 3,000,000 ≈ 0.00094 (roughly 1 in 1,070). Because the citable population figure (≥5.3M) is LARGER than 3M, the true outbreak rate is RARER than the displayed 1 in 1,070 (e.g. 2,807 / 5,300,000 ≈ 1 in 1,888) — the headline is therefore on the more-alarming side of the citable evidence, not conservative. Directionally, the rate for THC-product users specifically is higher than the all-vaper rate (~82% of cases; those who used only nicotine-based products had near-zero EVALI exposure), so restricting the denominator to THC users raises the rate while restricting the numerator does not. Post-vit-E-removal background EVALI rate is an order of magnitude lower. Low (0.0001): current (post-outbreak) background rate for regulated nicotine products. High (0.005): peak outbreak rate for those using illicit THC cartridges specifically.
Caveats: EVALI was an outbreak caused by a specific adulterant — vitamin E acetate — adde…
EVALI was an outbreak caused by a specific adulterant — vitamin E acetate — added to illicit THC vaping cartridges in the US black market. This was a US-specific phenomenon with no comparable international outbreak; other countries did not see equivalent EVALI clusters because their cannabis product markets differ. The outbreak-era rate (2019–2020) does not apply to the post-vitamin-E-removal period, and the caveats apply specifically to illicit/unregulated THC vaping cartridges, not to regulated nicotine e-cigarettes. Current teen nicotine vaping (7.8% of US high schoolers in 2024) carries a different and lower EVALI-specific risk profile. The long-term respiratory and cardiovascular effects of chronic nicotine vaping in adolescents are a separate and ongoing research question not captured by this entry, which is scoped to the specific acute EVALI outcome.
Related risks
Other risks on similar themes — for exploring related fears.
GLP-1 anesthesia aspiration
If you take a GLP-1 drug, will retained stomach contents cause you to aspirate during general anesthesia?
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
COVID-19
What are the odds of dying from COVID-19 over the course of the pandemic and endemic era?
Pick challenger
Between August 2019 and February 2020, the CDC tracked 2,807 hospitalizations and 68 deaths in the United States linked to e-cigarette or vaping product use — a cluster of severe lung injuries that came to be known as EVALI (e-cigarette or vaping product use–associated lung injury). In the Illinois–Wisconsin case series that first characterized the cluster, the median age of affected patients was 21, and about a quarter (26%) required intubation. By the time the CDC closed active surveillance in February 2020, 82% of confirmed cases involved THC-containing products, and vitamin E acetate — an oil-based thickening agent added to illicit THC vaping cartridges — was identified as the primary causative agent. Once the CDC and FDA issued warnings and states moved to remove adulterated products from circulation, the outbreak curve broke sharply.
The outbreak was genuine and serious, but it was causally specific in a way the subsequent fear has not always respected. EVALI was not a general risk of vaping; it was a risk of vaping from unregulated THC cartridges adulterated with a specific compound in the US supply chain at a specific moment. No comparable EVALI outbreak occurred in other countries, which did not have the same black-market THC vaping cartridge market. For US teens who vape regulated nicotine products — now the dominant form of teen vaping, at 7.8% of US high schoolers in 2024, down from 10.0% in 2023 — the specific EVALI risk profile from the outbreak era does not apply. The ongoing health risks of adolescent nicotine vaping are real but distinct: respiratory function effects, nicotine dependence, potential cardiovascular exposure, and the longer-term cancer question (covered in a separate entry, where the evidence supports a hazard but not yet a quantifiable lifetime probability) are documented concerns that fall outside the acute EVALI framework.
The roughest probability estimate for the outbreak period is approximately 1 in 1,070 across all US teenage and young-adult vapers, or higher still if the denominator is limited to those who used THC-containing products specifically. The current background EVALI rate for users of regulated nicotine products is an order of magnitude lower. The outbreak is the canonical example of a risk that was real, temporary, causally specific, and subsequently dissipated through intervention — yet the reputational effect on vaping broadly persists at a level uncalibrated to the current risk landscape.
Related tidbits
Even during the 2019-2020 EVALI outbreak, hospitalization ran at roughly 1 in 1,070 US teen and young-adult vapers, driven largely by illicit THC products. About 2,807 were hospitalized nationwide. A real injury, but far rarer than the outbreak coverage implied.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
2/4 sources independently verified verbatim against the cited source
-
[1] Centers for Disease Control and Prevention — Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products (EVALI) — Final Update Verified
Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products (EVALI) — Final Update- Statistic
2,807 hospitalized EVALI cases and 68 deaths reported to CDC by February 18, 2020; 82% involved THC products; vitamin E acetate identified as primary culprit- Excerpt
“"As of February 18, 2020, a total of 2,807 hospitalized EVALI cases or deaths have been reported to CDC from 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Among those with information on substances used, 82 percent reported using THC-containing products. Vitamin E acetate has been strongly linked to the EVALI outbreak. CDC, states, and the FDA recommend that people not use THC-containing e-cigarette or vaping products, particularly from informal sources like friends, family, or in-person or online dealers." ”
- Source data from
- 2020-02-25
- Accessed
- 2026-05-04 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- CDC final EVALI update — source of the 2,807 numerator only. 2,807 hospitalizations / an internal ~3 million working-estimate denominator of US teen + young adult vapers during the outbreak window ≈ 0.00094 (roughly 1 in 1,070). The denominator is not from this source; see the 2019 NYTS (Cullen et al.) entry, which anchors current youth vapers at ~5.3 million (a larger figure → rarer true rate). Since ~82% of cases involved THC products, the rate for THC-product users specifically is higher. The post-vit-E-removal era (post-2020) has a substantially lower rate; the figure here reflects the outbreak-era population-average risk across all teen/young-adult vapers.
-
[2] JAMA — e-Cigarette Use Among Youth in the United States, 2019
e-Cigarette Use Among Youth in the United States, 2019- Statistic
In 2019 (outbreak year), an estimated 4.1 million US high school students (27.5%) and 1.2 million middle school students (10.5%) currently used e-cigarettes — ~5.3 million youth vapers- Excerpt
“"An estimated 27.5% (95% CI, 25.3%-29.7%) of high school students and 10.5% (95% CI, 9.4%-11.8%) of middle school students reported current e-cigarette use. ... With the assumption that the prevalence estimates from this survey are nationally representative and could be used to project to national population totals for US high school and middle school students, the data would suggest that in 2019, an estimated 4.1 million high school students and 1.2 million middle school students currently use e-cigarettes." ”
- Source data from
- 2019-11-05
- Accessed
- 2026-07-14 · archived copy
- Calculation
- Cullen et al., JAMA 2019 (CDC-authored analysis of the 2019 National Youth Tobacco Survey, N=19,018). Establishes the outbreak-era youth vaping denominator: ~4.1 million high school + ~1.2 million middle school = ~5.3 million current youth e-cigarette users in 2019, the peak EVALI year. This is the citable anchor for the "millions of teen/young-adult vapers" denominator used in the headline. Note NYTS surveys only middle + high school students (all under 18); the EVALI case series had a median age of 21 (NEJM), so the true exposed population extends into young adults beyond this frame and is therefore ≥5.3 million. A larger true denominator makes the outbreak rate RARER than the displayed ~1 in 1,070 (which divides by an internal 3,000,000 working estimate) — the headline is thus, if anything, on the more-alarming side, not conservative.
-
[3] New England Journal of Medicine — Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin — Final Report Verified
Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin — Final Report- Statistic
Case series of 98 EVALI patients: median age 21, 89% used THC products, 95% hospitalized; 26% required intubation and mechanical ventilation- Excerpt
“"There were 98 case patients, 79% of whom were male; the median age of the patients was 21 years. A total of 95% of the patients were hospitalized, 26% underwent intubation and mechanical ventilation, and two deaths were reported. A total of 89% of the patients reported having used tetrahydrocannabinol products in e-cigarette devices, although a wide variety of products and devices was reported." ”
- Source data from
- 2020-03-05
- Accessed
- 2026-05-04 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- Layden et al. NEJM 2020 — final report from the two states that first identified the EVALI cluster. Establishes clinical severity (median age 21, 95% hospitalized, 26% intubated) and THC product involvement (89%). Confirms CDC's national pattern. Used to characterize the severity of the outcome (serious_harm) and the THC-product causation.
-
[4] CDC / Morbidity and Mortality Weekly Report — Tobacco Product Use Among US Middle and High School Students — National Youth Tobacco Survey, 2024
Tobacco Product Use Among US Middle and High School Students — National Youth Tobacco Survey, 2024See all 2 Likelier entries citing this source →
- Statistic
7.8% of US high school students currently used e-cigarettes in 2024 (down from 10.0% in 2023; ~1.21 million students); e-cigarettes remained the most commonly used tobacco product among youth- Excerpt
“"E-cigarettes were the most commonly used product (7.8%) among high school students. Among high school students, declines occurred in current use of any tobacco product (from 12.6% to 10.1%) and e-cigarettes (from 10.0% to 7.8%). Overall, current e-cigarette use decreased (from 1.56 million to 1.21 million) high school students from 2023 to 2024." ”
- Source data from
- 2024-10-17
- Accessed
- 2026-05-04 · archived copy
- Calculation
- CDC NYTS 2024. Provides the current teen vaping prevalence denominator context (7.8% of high schoolers, ~1.21 million students). The decline from 10.0% (2023) to 7.8% (2024) — and the broader fall from the ~27% peak years earlier — confirms that the outbreak-era exposure scenario is no longer current. The current background EVALI rate among regulated nicotine vapers is substantially lower; the normalized rate reflects the outbreak-era THC-vaping scenario.